Impact of immune cell, state of cytokine regulation and intestinal biocenosis on the fibrotic processes in chronic diffuse liver disease

Authors

  • V.I. Didenko SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine
  • O.M. Tatarchuk SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine
  • E.V. Zygalo SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine http://orcid.org/0000-0001-5026-0992
  • I.S. Konenko SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine
  • V.B. Yagmur SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine http://orcid.org/0000-0002-1738-4624

DOI:

https://doi.org/10.22141/2308-2097.55.1.2021.229433

Keywords:

immunoregulation, inflammatory process, liver fibrosis, intestinal microbiota, syndrome of intestinal bacterial overgrowth, inflammatory and anti-inflammatory cytokines, chronic diffuse liver disease

Abstract

Background. It is known that disorders of the intestinal microbiota in patients with chronical liver disease (CLD) are associated with immune dysregulation. The process begins with a violation of the intestinal microbiota, leading to the development of immunodeficiency, affecting the course of the underlying disease (with progression of liver fibrosis). Besides, violation of intestinal biocenosis is a consequence of adverse effects on the body and its microflora state resulting in reduced immune function. The purpose of the study was to determine the mechanisms of cytokine regulation in the body of patients with CLD in the formation and progression of liver fibrosis depending on the damage of the intestinal microbiota. Materials and methods. Seventy-six patients with CLD were examined. All patients underwent a hydrogen breath test (HBT), shear wave elastography; the liver stiffness parameters were studied on a FibroScan. Depending on the indices obtained and the presence of small intestinal bacterial overgrowth (SIBO) in the small intestine in the formation and progression of liver fibrosis, the patients were divided into groups. The subpopulation of lymphocytes — CD4 and CD8 was determined using monoclonal antibodies from the company “Sorbent TM”. The serum level of IL-6, IL-10, TNF-α was determined by enzyme-linked immunosorbent assay (ELISA) using the reagent kits from the company “Vector-BEST”. Results. The elevated levels of inflammatory cytokines (IL-6 and TNF-α) do not induce the secretion of anti-inflammatory cytokines (IL-10) with the presence of SIBO, which leads to the maintenance of inflammation and progression of liver fibrosis depending on intestinal biocenosis (a correlation was found between liver stiffness and hydrogen levels r = 0.79; р < 0.001). In patients with CLD, the violation of the cellular component of immunity is associated with an impairment of the intestinal microbiota, as evidenced by correlations with the hydrogen level (ppm): CD8+ (r = –0.439; p < 0.05) and CD4/CD8 (r = +0.492; p < 0.05). Conclusions. Impaired immunoregulatory mechanisms contribute to the fibrotic processes with subsequent violation of the gut microbiota.

Downloads

Download data is not yet available.

References

Tkach SM, Cheverda TL, Kaznоdiy AV. The role of enterohepatic association and intestinal microbiota in the development of non-alcoholic fatty liver disease. Modern Gastroenterology. 2015;(85):96-109. (in Russian).

Parkash O, Saeed S. Molecular basis for pathogenesis of steatohepatitis: contemporary understanding and new insights. In: Valenzuela Baez, editor. Non-alcoholic fatty liver disease: molecular bases, prevention and treatment. London, UK: Intech Open; 2018. doi:10.5772/intechopen.71405. 54 p.

Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386. doi:10.1038/s41575-019-0144-8.

Mauss S, Berg T, Rockstroh J. Hepatology: a clinical textbook. 6th ed. Sydney: Flying Publisher; 2015. 655 p.

Caballería L, Pera G, Arteaga I, et al. High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. Clin Gastroenterol Hepatol. 2018 Jul;16(7):1138-1145.e5. doi:10.1016/j.cgh.2017.12.048.

Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017 Jan;37(Suppl 1):85-89. doi:10.1111/liv.13301.

Ivanov AS, Garmasch IV, Arisheva OS, et al. Immune-inflammatory and genetic factors in the development of alcoholic liver fibrosis. Klinicheskaia farmakologiia i terapiia. 2018;27(5):30-35. doi:10.32756/0869- 5490-2018-5-30-35. (in Russian).

Kruglov AA, Nedospasov SA. Microbiota, intestinal immunity, and mouse bustle. Acta Naturae.2014;6(20):6-8. doi:10.32607/20758251-2014-6-1-6-8.

Goretskaya MV. Synthetic functions of the liver and humoral factors of the immune system. Journal of the Grodno State Medical University. 2008;(2):7-11. (in Russain).

Kornienko EA. Intestinal microbiota as a key factor in the formation of immunity and tolerance. Probiotics capabiliti. Meditsinskiy sovet. 2020;(10):92-100. doi:10.21518/2079-701х-2020-10-92-100. (in Russian).

Shi N, Li N, Duan X, Niu H. Interaction between the gut microbiome and mucosal immune system. Mil Med Res. 2017 Apr 27;4:14. doi:10.1186/s40779-017-0122-9.

Clavel T, Gomes-Neto JC, Lagkouvardos I, Ramer-Tait AE. Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. Immunol Rev. 2017 Sep;279(1):8-22. doi:10.1111/imr.12578.

Mannaa FA, Abdel-Wahhab KG. Physiological potential of cytokines and liver damages. Hepatoma Res 2016;2:131-143. doi:10.20517/2394-5079.2015.58.

Niederreiter L, Tigl H. Cytokines and fatty liver diseases. Liver Research.2018;2(1):14-20. doi:10.1016/j.livres.2018.03.003.

Ledochowski M. Hydrogen Breath tests. Innsbruck, Austria: Akademie Publishing House; 2008. 20 p.

Stepanov JuM, Didenko VI, Konenko IS, Jagmur VB, Petishko OP, Orlovskyj DV. Sposib diagnostyky fibrozu pechinky u hvoryh na hronichnyj gepatyt C [Method for diagnosing liver fibrosis in patients with chronic hepatitis C]. Patent UA № 140554, 2020. (in Ukrainian).

Stepanov JuM, Didenko VI, Konenko IS, Jagmur VB, Petishko OP. Sposib diagnostyky steatozu pechinky u hvoryh na nealkogol'nu zhyrovu hvorobu pechinky [Method for diagnosing liver steatosis in patients with non-alcoholic fatty liver disease]. Patent UA № 136479, 2019. (in Ukrainian).

Published

2021-09-06

How to Cite

Didenko, V., Tatarchuk, O., Zygalo, E., Konenko, I., & Yagmur, V. (2021). Impact of immune cell, state of cytokine regulation and intestinal biocenosis on the fibrotic processes in chronic diffuse liver disease. GASTROENTEROLOGY, 55(1), 26–31. https://doi.org/10.22141/2308-2097.55.1.2021.229433

Issue

Section

Original Researches

Most read articles by the same author(s)

1 2 3 4 5 6 > >>